Air contamination, syringe contamination, and cross-contamination when using an automatic compounding device for sensitizing drugs

Paul Sessink, Gerardo Cajaraville, Maria José Tamés, Ana Riestra, Andrea Alcorta, Naiara Telleria, Jaione Grisaleña
{"title":"Air contamination, syringe contamination, and cross-contamination when using an automatic compounding device for sensitizing drugs","authors":"Paul Sessink, Gerardo Cajaraville, Maria José Tamés, Ana Riestra, Andrea Alcorta, Naiara Telleria, Jaione Grisaleña","doi":"10.1515/pthp-2023-0002","DOIUrl":null,"url":null,"abstract":"Abstract Objectives To measure cross-contamination between batches of different sensitizing drugs, contamination on the outside of compounded syringes, and drug concentrations in environmental air when using an automated compounding device. Methods One batch of piperacillin/tazobactam syringes followed by one batch of meropenem syringes were compounded daily for three consecutive days by one operator. For each batch two hundred syringes were filled. During each batch, three stationary air samples (two inside and one outside the compounding device), and one personal air sample were collected. At the end of the compounding process, the outside of 40 syringes was tested for drug contamination by wipe sampling. The drug compounded was checked for cross-contamination with the other drug compounded in the previous batch. Liquid chromatography tandem mass spectrometry was used for the analysis of piperacillin and meropenem. Results Piperacillin was measured in environmental air inside the device (8.1–335 ng/m 3 ), outside the device (5.2–21 ng/m 3 ), and in the personal air samples of the operator (15 and 155 ng/m 3 ) during two batches. Meropenem was not detected during meropenem compounding. Piperacillin was found in the air samples of the operator during two batches (12 and 15 ng/m 3 ). Meropenem was not detected in any of the air samples. The drug compounded was found on the outside of the syringes for all batches (piperacillin: 1.35–30 ng/cm 2 ; meropenem: 0.07–0.65 ng/cm 2 ). Piperacillin was detected on the syringes in all meropenen batches (0.56–11 ng/cm 2 ), and meropenen in two piperacillin batches (0.07 and 0.46 ng/cm 2 ). The drug solutions show no cross-contamination with the other drug for any of the batches. Conclusions Cross-contamination was not found and the drug concentrations in environmental air were below the Occupational Exposure Limit of 0.1 mg/m 3 . The automatic compounding device meets the criteria for a safe compounding of sensitizing drugs for patient and operator.","PeriodicalId":19802,"journal":{"name":"Pharmaceutical Technology in Hospital Pharmacy","volume":"52 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Technology in Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/pthp-2023-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Objectives To measure cross-contamination between batches of different sensitizing drugs, contamination on the outside of compounded syringes, and drug concentrations in environmental air when using an automated compounding device. Methods One batch of piperacillin/tazobactam syringes followed by one batch of meropenem syringes were compounded daily for three consecutive days by one operator. For each batch two hundred syringes were filled. During each batch, three stationary air samples (two inside and one outside the compounding device), and one personal air sample were collected. At the end of the compounding process, the outside of 40 syringes was tested for drug contamination by wipe sampling. The drug compounded was checked for cross-contamination with the other drug compounded in the previous batch. Liquid chromatography tandem mass spectrometry was used for the analysis of piperacillin and meropenem. Results Piperacillin was measured in environmental air inside the device (8.1–335 ng/m 3 ), outside the device (5.2–21 ng/m 3 ), and in the personal air samples of the operator (15 and 155 ng/m 3 ) during two batches. Meropenem was not detected during meropenem compounding. Piperacillin was found in the air samples of the operator during two batches (12 and 15 ng/m 3 ). Meropenem was not detected in any of the air samples. The drug compounded was found on the outside of the syringes for all batches (piperacillin: 1.35–30 ng/cm 2 ; meropenem: 0.07–0.65 ng/cm 2 ). Piperacillin was detected on the syringes in all meropenen batches (0.56–11 ng/cm 2 ), and meropenen in two piperacillin batches (0.07 and 0.46 ng/cm 2 ). The drug solutions show no cross-contamination with the other drug for any of the batches. Conclusions Cross-contamination was not found and the drug concentrations in environmental air were below the Occupational Exposure Limit of 0.1 mg/m 3 . The automatic compounding device meets the criteria for a safe compounding of sensitizing drugs for patient and operator.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用致敏药物的自动配药装置时的空气污染、注射器污染和交叉污染
摘要目的测定不同致敏药物批次间的交叉污染情况、复合注射器外部的污染情况以及使用自动配药装置时环境空气中的药物浓度。方法由1名操作人员每日配药1批哌拉西林/他唑巴坦,随后配药1批美罗培南,连续3 d。每批装200支注射器。每批采集固定空气样品3份(2份在配药装置内,1份在配药装置外),1份个人空气样品。在配制过程结束时,通过擦拭取样对40支注射器的外部进行药物污染检测。检查该配药是否与前一批配药的另一种配药交叉污染。采用液相色谱串联质谱法对哌拉西林和美罗培南进行分析。结果检测了两批设备内环境空气(8.1 ~ 335 ng/m 3)、设备外环境空气(5.2 ~ 21 ng/m 3)和操作人员个人空气样品(15和155 ng/m 3)中哌拉西林的含量。复方美罗培南未检出美罗培南。在两个批次(12和15 ng/ m3)的操作人员空气样本中发现了哌拉西林。空气样本中没有检测到美罗培南。在所有批次的注射器外均发现复方药物(哌拉西林:1.35-30 ng/ cm2;美罗培南:0.07-0.65 ng/ cm2)。美罗培林所有批次(0.56 ~ 11 ng/ cm2)的注射器中均检测到哌拉西林,两批次(0.07和0.46 ng/ cm2)的注射器中均检测到哌拉西林。任何批次的药物溶液均未显示与其他药物交叉污染。结论未发现交叉污染,环境空气中药物浓度均低于0.1 mg/ m3的职业暴露限值。该自动配药装置满足对患者和操作人员安全配药的标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
7
审稿时长
12 weeks
期刊最新文献
Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL) Physicochemical stability of durvalumab (Imfinzi®) concentrate for solution in original vials after first opening Semi-automatic COVID-19 vaccine preparation for upscaling of vaccination: a descriptive study Assessment of the relevance of osmolality measurement as a criterion for the stability of solutions Use of a liquid chromatography-tandem mass spectrometry method to assess the concentration of epinephrine, norepinephrine, and phenylephrine stored in plastic syringes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1